Category: Expert Perspectives in Atopic Dermatitis

Andrew Mastro, MS, PA-C, addresses the psychosocial impact of chronic hand eczema and highlights emerging treatments like biologics and JAK inhibitors. Topics Covered: Quality of

Andrew Mastro, MS, PA-C, addresses the psychosocial impact of chronic hand eczema and highlights emerging treatments like biologics and JAK inhibitors. Topics Covered: Quality of

Dr. Lisa Swanson shares insights on maximum-use data for ruxolitinib cream in children ages 2–11 with atopic dermatitis, highlighting safety and efficacy. Topics Covered: Ruxolitinib

Melodie Young, MSN, RN, ANP-C, discusses treating young children with atopic dermatitis and counseling caregivers on potential side effects. Topics Covered: Pediatric atopic dermatitis treatment

Melodie Young discusses the logistics of gaining access to newer medications through speciality pharmacies for patients with atopic dermatitis.

Andrea Nguyen, PA-C, MS, discusses how the internet and social media has contributed to more in-depth discussion with her patients regarding treatment for atopic dermatitis.

TJ Chao breaks down the black box warnings for ruxolitinib cream 1.5% and discusses the importance in communicating the specifics of these warnings to patients.

Mr. Chao discusses the reliability of ruxolitinib cream 1.5% in treating patients with atopic dermatitis. He emphasized how well it is tolerated by patients, as

Dr. Matthew Zirwas reviews atopic dermatitis treatments that have been essential in providing immediate improvement in itch leading to a sense of control in his

Dr. Silverberg discusses how to safely counsel patients when deciding between topical versus oral JAK inhibitors for the treatment of atopic dermatitis.

Peter Lio, MD, of Medical Dermatology Associates of Chicago in Chicago, Illinois, discusses recent innovations in atopic dermatitis therapies with regard to JAK inhibitors. Dr.